Efforts to develop therapies against Toxoplasma reactivation have been hampered by the lack of an in vitro model of bradyzoite recrudescence. To overcome this issue, we established a new ex vivo model of bradyzoite recrudescence using bradyzoites from an unadapted Type II ME49 strain isolated from murine brain tissue to infect human foreskin fibroblasts and neonatal murine astrocytes. Bradyzoite infection of both host cell types produced two sequential tachyzoite growth stages that appeared similar to previous sporozoite in vitro infections; a fast-growing stage was followed by spontaneous formation of a slowergrowing stage. In astrocytes, but not in fibroblasts, there was evidence of second bradyzoite to bradyzoite recrudescent pathway that occurred simultaneously with the bradyzoite to tachyzoite pathway.Thus, the host cell environment strongly influenced the pathway of bradyzoite recrudescence. Infections of mice with either the fast-growing or slow-growing recrudescent tachyzoites showed progressive decreases in brain cyst formation that could be fully recovered using serial tissue cyst passage demonstrating the loss of developmental capacity was reversible. By contrast, poor tissue cyst formation of laboratory-adapted tachyzoites was not reversible by these approaches indicating developmental incompetence was permanent in these strains. In order to develop methods to distinguish strain developmental competency, we identified Toxoplasma genes highly expressed in ME49EW in vivo tissue cysts and developed a qPCR approach that differentiates immature from mature bradyzoites. In summary, the results presented describe a new ex vivo bradyzoite recrudescence model that fully captures the reported growth and developmental processes observed during toxoplasmosis reactivation in vivo opening the door to the further study of these important features of the Toxoplasma intermediate life cycle.